Table 1.
Clinical trials of MSCs application in kidney disease
| Condition | Aim of study | Enrolment | Phase | Status | Outcomes | ClinicalTrials.gov Identifier |
|---|---|---|---|---|---|---|
| AKI | To demonstrate the safety of allogeneic MSCs in patients who are at high risk of developing AKI following cardiac surgery | 16 | Phase I | Completed | Safe and efficient | NCT00733876 |
| To evaluate the safety and efficacy of allogeneic MSCs for the treatment of AKI after cardiac surgery | 156 | Phase II | Terminated | Safe but not efficient | NCT01602328 | |
| To determine the safety and tolerability of extracorporeal MSCs in subjects with AKI receiving continuous renal replacement therapy | 24 | Phase I | Recruiting | NCT03015623 | ||
| CKD | To provide confirmation of the safety of MSCs in patients with chronic renal failure due to ADPKD | 6 | Phase I | Completed | Safe and efficient | NCT02166489 |
| To develop a novel treatment via intra‐arterial MSC injection in atherosclerotic RVD patients | 28 | Phase I | Completed | Safe and efficient | NCT01840540 | |
| To explore the safety and efficacy of MSC transplantation in refractory SLE | 13 | Phase I & II | Completed | Safe and efficient | NCT00698191 | |
| To assess the safety and efficacy of MSCs in patients with active and refractory SLE | 40 | Phase I & II | Completed | Safe and efficient | NCT01741857 | |
| To investigate the efficacy of MSCs for treatment of lupus nephritis | 18 | Phase II | Terminated | Safe but not efficient | NCT01539902 | |
| To assess the safety, tolerability and therapeutic effects of mesenchymal precursor cells in patients with moderate to severe DN | 30 | Phase I & II | Completed | Safe but not efficient | NCT01843387 | |
| To investigate the safety, feasibility, tolerability and efficacy of MSCs in subjects with progressive DN | 48 | Phase I & II | Recruiting | NCT02585622 | ||
| To determine whether intra‐renal delivery of MSCs would further enhance changes in single kidney blood flow and restoration of kidney function in human subjects with advanced RVD | 42 | Phase I | Not yet recruiting | NCT02266394 | ||
| To test the safety of intra‐parenchymal Wharton jelly‐derived MSC injection in the treatment of DN | 20 | Phase I & II | Not yet recruiting | NCT03288571 | ||
| To assess the safety, tolerability and efficacy of intra‐arterially delivered MSCs in patients with progressive DN | 30 | Phase I | Not yet recruiting | NCT03840343 | ||
| To investigate the treatment effects of MSCs in chronic renal failure patients | 100 | Not Applicable | Recruiting | NCT03321942 | ||
| To evaluate the safety and efficacy of MSCs for treatment of adults with active proliferative LN | 36 | Phase II | Not yet recruiting | NCT03673748 | ||
| To investigate the efficacy and safety of MSC transplantation in the treatment of LN compared with mycophenolate mofetil | 230 | Phase II | Not yet recruiting | NCT03580291 | ||
| To demonstrate the safety and efficacy of MSCs in patients with SLE and LN | 30 | Not Applicable | Not yet recruiting | NCT03458156 | ||
| To assess the safety and tolerability of MSCs (CS20AT04) in subjects with LN | 6 | Phase I | Not yet recruiting | NCT03174587 |
Abbreviations: ADPKD, autosomal dominant polycystic kidney disease; AKI, acute kidney injury; CKD, chronic kidney disease; DN, diabetic nephropathy; DN, diabetic nephropathy; LN, lupus nephritis; MSCs, mesenchymal stem cells; RVD, renal vascular disease; SLE, systemic lupus erythematosus.